The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Open accessAbstract
Cisplatin and other platinum-based chemotherapeutic drugs have been used extensively for the treatment of human cancers such as bladder, blood, breast, cervical, esophageal, head and neck, lung, ovarian, testicular cancers, and sarcoma. Cisplatin is commonly administered intravenously as a first-line chemotherapy for patients suffering from various malignancies. Upon absorption into the cancer cell, cisplatin interacts with cellular macromolecules and exerts its cytotoxic effects through a series of biochemical mechanisms by binding to Deoxyribonucleic acid (DNA) and forming intra-strand DNA adducts leading to the inhibition of DNA synthesis and cell growth. Its primary molecular mechanism of action has been associated with the induction of both intrinsic and extrinsic pathways of apoptosis resulting from the production of reactive oxygen species through lipid peroxidation, activation of various signal transduction pathways, induction of p53 signaling and cell cycle arrest, upregulation of pro-apoptotic genes/proteins, and down-regulation of proto-oncogenes and anti-apoptotic genes/proteins. Despite great clinical outcomes, many studies have reported substantial side effects associated with cisplatin monotherapy, while others have shown substantial drug resistance in some cancer patients. Hence, new formulations and several combinational therapies with other drugs have been tested for the purpose of improving the clinical utility of cisplatin. Therefore, this review provides a comprehensive understanding of its molecular mechanisms of action in cancer therapy and discusses the therapeutic approaches to overcome cisplatin resistance and side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cheng, Q., Liao, M., Hu, H., Li, H., & Wu, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489806 · Cited by 42
RetractedNanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Transcriptional Regulation by Nrf2
Tonelli, C., Chio, I. I. C., & Tuveson, D. A. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7342 · Cited by 2,192
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & Harmon, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j · Cited by 2,132
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
The JNK signal transduction pathway
Weston, C. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00258-1 · Cited by 1,528
Doxorubicin: The good, the bad and the ugly effect
Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803312 · Cited by 1,509
Oxidative stress and cancer: An overview
Sosa, V., Moliné, T., Somoza, R., Paciucci, R., Kondoh, H., & LLeonart, M. E. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.10.004 · Cited by 1,439
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
Kansanen, E., Kuosmanen, S. M., Leinonen, H., & Levonen, A.-L. (2013) · Redox Biology · doi:10.1016/j.redox.2012.10.001 · Cited by 1,313
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
Cisplatin Nephrotoxicity: A Review
Yao, X., Panichpisal, K., Kurtzman, N., & Nugent, K. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31812dfe1e · Cited by 1,251
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,068
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7617 · Cited by 872
Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42.
(1987) · PubMed · Cited by 851
Integrating high-throughput and computational data elucidates bacterial networks
Covert, M. W., Knight, E. M., Reed, J. L., Herrgard, M. J., & Palsson, B. O. (2004) · Nature · doi:10.1038/nature02456 · Cited by 792
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Biochemical Mechanisms of Cisplatin Cytotoxicity
Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., & Perez, J. M. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007779314044 · Cited by 649
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601
Targeting calcium signaling in cancer therapy
Cui, C., Merritt, R., Fu, L., & Pan, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.11.001 · Cited by 598
Fernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 579
Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?
Gonzalez, V. M., Fuertes, M. A., Alonso, C., & Perez, J. M. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09232-0 · Cited by 578
Protein Kinase C δ Activates the MEK-ERK Pathway in a Manner Independent of Ras and Dependent on Raf
Ueda, Y., Hirai, S.-I., Osada, S.-I., Suzuki, A., Mizuno, K., & Ohno, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23512 · Cited by 572
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Mechanisms of cisplatin-induced ototoxicity and prevention
Rybak, L. P., Whitworth, C. A., Mukherjea, D., & Ramkumar, V. (2007) · Hearing Research · doi:10.1016/j.heares.2006.09.015 · Cited by 563
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
The Discovery and Development of Cisplatin
Alderden, R. A., Hall, M. D., & Hambley, T. W. (2006) · Journal of Chemical Education · doi:10.1021/ed083p728 · Cited by 532
Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling
Mandic, A., Hansson, J., Linder, S., & Shoshan, M. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210284200 · Cited by 509
Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H. A., DeConti, R. C., Ensley, J., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.057 · Cited by 496
Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents
Kharbanda, S., Ren, R., Pandey, P., Shafman, T. D., Feller, S. M., Weichselbaum, R. R., & Kufe, D. W. (1995) · Nature · doi:10.1038/376785a0 · Cited by 485
Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development
Lee, J., Prohaska, J. R., & Thiele, D. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111058698 · Cited by 472
Lieberthal, W., Triaca, V., & Levine, J. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.270.4.f700 · Cited by 449
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
Kryczek, I., Lin, Y., Nagarsheth, N., Peng, D., Zhao, L., Zhao, E., Vatan, L., Szeliga, W., Dou, Y., Owens, S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.010 · Cited by 389
Analysis of the glutathione S-transferase (GST) gene family
Nebert, D. W., & Vasiliou, V. (2004) · Human Genomics · doi:10.1186/1479-7364-1-6-460 · Cited by 387
Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin
Aldossary, S. A. (2019) · Biomedical and Pharmacology Journal · doi:10.13005/bpj/1608 · Cited by 366
Miao, T., Wang, J., Zeng, Y., Liu, G., & Chen, X. (2018) · Advanced Science · doi:10.1002/advs.201700513 · Cited by 362
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Strathdee, G., MacKean, M. J., Illand, M., & Brown, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350
Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells
Periyasamy-Thandavan, S., Jiang, M., Wei, Q., Smith, R., Yin, X.-M., & Dong, Z. (2008) · Kidney International · doi:10.1038/ki.2008.214 · Cited by 322
Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma
Perilongo, G., Maibach, R., Shafford, E., Brugieres, L., Brock, P., Morland, B., de Camargo, B., Zsiros, J., Roebuck, D., Zimmermann, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810613 · Cited by 320
Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Donnelly, A., & Blagg, B. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242895 · Cited by 313
Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters, G. J., Bergman, A. M., van Haperen, V. W. T. R., Veerman, G., Kuiper, C. M., & Braakhuis, B. J. M. (1995) · PubMed · Cited by 312
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., & Steinberg, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.968 · Cited by 312
Benhar, M., Dalyot, I., Engelberg, D., & Levitzki, A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.6913-6926.2001 · Cited by 306
Erhardt, P., Schremser, E. J., & Cooper, G. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5308 · Cited by 306
ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair
Ahmad, A., Robinson, A. R., Duensing, A., van Drunen, E., Beverloo, H. B., Weisberg, D. B., Hasty, P., Hoeijmakers, J. H. J., & Niedernhofer, L. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00293-08 · Cited by 299
Vitamin D: More Than a “Bone-a-Fide” Hormone
Sutton, A. L. M., & MacDonald, P. N. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0363 · Cited by 294
Baik, M.-H., Friesner, R. A., & Lippard, S. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036960d · Cited by 293
Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin
Persons, D. L., Yazlovitskaya, E. M., & Pelling, J. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004267200 · Cited by 290
Kuhlmann, M., Burkhardt, G., & Kohler, H. (1997) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/12.12.2478 · Cited by 290
Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals
Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284
Hamada, C., Tanaka, F., Ohta, M., Fujimura, S., Kodama, K., Imaizumi, M., & Wada, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.017 · Cited by 284
Rose, P. G., Ali, S., Watkins, E., Thigpen, J. T., Deppe, G., Clarke-Pearson, D. L., & Insalaco, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4532 · Cited by 284
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90545.2008 · Cited by 283
The roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
Choi, Y.-M., Kim, H.-K., Shim, W., Anwar, M. A., Kwon, J.-W., Kwon, H.-K., Kim, H. J., Jeong, H., Kim, H. M., Hwang, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135083 · Cited by 279
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway
Farkhondeh, T., Folgado, S. L., Pourbagher-Shahri, A. M., Ashrafizadeh, M., & Samarghandian, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110234 · Cited by 273
Nephrotoxicity and Hydration Management for Cisplatin, Carboplatin, and Ormaplatin
Cornelison, T. L., & Reed, E. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1184 · Cited by 270
Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., & Cullen, K. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1037 · Cited by 267
Nowak, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206373200 · Cited by 265
Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies
El-Awady, E.-S. E., Moustafa, Y. M., Abo-Elmatty, D. M., & Radwan, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.085 · Cited by 260
Cisplatin-Based Chemotherapy of Human Cancers.
Brown, A. M., Kumar, S., & Tchounwou, P. B. (2019) · PubMed · Cited by 256
Self-citationAutophagy Guards Against Cisplatin-Induced Acute Kidney Injury
Takahashi, A., Kimura, T., Takabatake, Y., Namba, T., Kaimori, J., Kitamura, H., Matsui, I., Niimura, F., Matsusaka, T., Fujita, N., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.001 · Cited by 253
Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249
Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Kalantari, M., Mohammadinejad, R., Javaheri, T., & Sethi, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114002 · Cited by 248
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, D. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243
Chen, K.-J., Lin, S.-Z., Zhou, L., Xie, H.-Y., Zhou, W.-H., Taki-Eldin, A., & Zheng, S.-S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024671 · Cited by 240
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90185-m · Cited by 237
Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M. J., Gjerset, R., & Mercola, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14041 · Cited by 229
Aapro, M. S., Martin, C., & Hatty, S. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199803000-00001 · Cited by 228
Dong, J., Sulik, K. K., & Chen, S.-Y. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.2019 · Cited by 226
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
Welsh, C., Day, R., McGurk, C., Masters, J. R. W., Wood, R. D., & Köberle, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20134 · Cited by 215
p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
Grossi, V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9744 · Cited by 214
Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy
Lee, S.-M., O’Halloran, T. V., & Nguyen, S. T. (2010) · Journal of the American Chemical Society · doi:10.1021/ja107333g · Cited by 213
Ling, X., Chen, X., Riddell, I. A., Tao, W., Wang, J., Hollett, G., Lippard, S. J., Farokhzad, O. C., Shi, J., & Wu, J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01924 · Cited by 209
Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E., Morselli, E., Senovilla, L., Araujo, N., Pinna, G., Larochette, N., Zamzami, N., et al. (2008) · Oncogene · doi:10.1038/onc.2008.63 · Cited by 208
Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines
Brown, R., Clugston, C., Edlin, A., Vasey, P., Kaye, S. B., Burns, P., & Vojtěšek, B. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550428 · Cited by 202
Cisplatin-Induced Hepatotoxicity Is Enhanced by Elevated Expression of Cytochrome P450 2E1
Lu, Y., & Cederbaum, A. I. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj031 · Cited by 202
Apoptotic mechanisms in acute renal failure
Ueda, N., Kaushal, G. P., & Shah, S. V. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00311-9 · Cited by 201
The potential of protein kinase C as A target for anticancer treatment
Basu, A. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90070-t · Cited by 197
Lan, X., She, J., Lin, D.-A., Xu, Y., Li, X., Yang, W.-F., Lui, V. W. Y., Jin, L., Xie, X., & Su, Y.-X. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b12926 · Cited by 197
Sedletska, Y., Giraud-Panis, M.-J., & Malinge, J.-M. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053765967 · Cited by 195
An Msh2 Point Mutation Uncouples DNA Mismatch Repair and Apoptosis
Lin, D. P., Wang, Y., Scherer, S. J., Clark, A. B., Yang, K., Avdievich, E., Jin, B., Werling, U., Parris, T., Kurihara, N., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2957 · Cited by 195
Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells
Wu, H.-M., Jiang, Z.-F., Ding, P.-S., Shao, L.-J., & Liu, R.-Y. (2015) · Scientific Reports · doi:10.1038/srep12291 · Cited by 179
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery
Muggia, F. M., Bonetti, A., Hoeschele, J. D., Rozencweig, M., & Howell, S. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.7481 · Cited by 177
Hayakawa, J., Ohmichi, M., Kurachi, H., Ikegami, H., Kimura, A., Matsuoka, T., Jikihara, H., Mercola, D., & Murata, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31648 · Cited by 175
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells
Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K. R., Kassack, M. U., Osmak, M., & Jaehde, U. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.003 · Cited by 174
Zhang, Y., Fu, X., Jia, J., Wikerholmen, T., Xi, K., Kong, Y., Wang, J., Chen, H., Ma, Y., Li, Z., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c12042 · Cited by 174
Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope
Perfettini, J.-L., Castedo, M., Nardacci, R., Ciccosanti, F., Boya, P., Roumier, T., Larochette, N., Piacentini, M., & Kroemer, G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041502 · Cited by 168
Mirrahimi, M., Abed, Z., Beik, J., Shiri, I., Shiralizadeh Dezfuli, A., Mahabadi, V. P., Kamran Kamrava, S., Ghaznavi, H., & Shakeri-Zadeh, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.005 · Cited by 168
Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility
Yang, G., Scherer, S. J., Shell, S. S., Yang, K., Kim, M., Lipkin, M., Kucherlapati, R., Kolodner, R. D., & Edelmann, W. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.024 · Cited by 166
Cho, J.-M., Manandhar, S., Lee, H.-R., Park, H.-M., & Kwak, M.-K. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.022 · Cited by 166
Huang, R. S., Duan, S., Shukla, S. J., Kistner, E. O., Clark, T. A., Chen, T. X., Schweitzer, A. C., Blume, J. E., & Dolan, M. E. (2007) · The American Journal of Human Genetics · doi:10.1086/519850 · Cited by 163
Niho, S., Kenmotsu, H., Sekine, I., Ishii, G., Ishikawa, Y., Noguchi, M., Oshita, F., WATANABE, S.-I. I., Nakajima, R., Tada, H., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828f6989 · Cited by 160
Targeted Delivery of Cisplatin to Lung Cancer Using ScFvEGFR-Heparin-Cisplatin Nanoparticles
Peng, X.-H., Wang, Y., Huang, D., Wang, Y., Shin, H. J., Chen, Z., Spewak, M. B., Mao, H. Z., Wang, X., Wang, Y., et al. (2011) · ACS Nano · doi:10.1021/nn202410f · Cited by 160
Wu, H., Jin, H., Wang, C., Zhang, Z., Ruan, H., Sun, L., Yang, C., Li, Y., Qin, W., & Wang, C. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b16844 · Cited by 159
Zhu, H., Zhang, H., Jin, F., Fang, M., Huang, M., Yang, C. S., Chen, T., Fu, L., & Pan, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.1903 · Cited by 158
Tyagi, A., Agarwal, C., Chan, D., & Agarwal, R. (2004) · Oncology Reports · doi:10.3892/or.11.2.493 · Cited by 158
Vitamin D analogs: Therapeutic applications and mechanisms for selectivity
Brown, A. J., & Slatopolsky, E. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.04.001 · Cited by 157
Dreyfuss, A. I., Clark, J. R., Fallon, B. G., Posner, M. R., Norris, C. M., & Miller, D. (1987) · Cancer · Cited by 155
Zhang, X., Qi, Z., Yin, H., & Yang, G. S. (2019) · Theranostics · doi:10.7150/thno.29673 · Cited by 154
Guo, X., Kang, X., Wang, Y.-Q., Zhang, X., Li, C., Yang, L., & Du, L. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.007 · Cited by 153
Melatonin as a potential modulator of Nrf2
Ahmadi, Z., & Ashrafizadeh, M. (2019) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12498 · Cited by 153
Roles of p38α mitogen‐activated protein kinase in mouse models of inflammatory diseases and cancer
Gupta, J. R. P., & Nebreda, Á. R. (2015) · FEBS Journal · doi:10.1111/febs.13250 · Cited by 152
Guo, S., Wang, Y., Miao, L., Xu, Z., Lin, C. M., Zhang, Y., & Huang, L. (2013) · ACS Nano · doi:10.1021/nn403606m · Cited by 149
Xu, Y., Han, X., Li, Y., Min, H., Zhao, X., Zhang, Y., Qi, Y., Shi, J. Y., Qi, S., Bao, Y., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b07032 · Cited by 149
Cytoplasmic signalling by the c‐Abl tyrosine kinase in normal and cancer cells
Sirvent, A., Bénistant, C., & Roche, S. (2008) · Biology of the Cell · doi:10.1042/bc20080020 · Cited by 148
Fraval, H. N. A., Rawlings, C., & Roberts, J. J. (1978) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(78)90014-3 · Cited by 143
Walch‐Rückheim, B., Mavrova, R., Henning, M., Vicinus, B., Kim, Y.-J., Bohle, R. M., Juhasz‐Böss, I., Solomayer, E., & Smola, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0732 · Cited by 143
Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
Khan, M. M., Madni, A., Torchilin, V. P., Filipczak, N., Pan, J., Tahir, N., & Shah, H. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1642420 · Cited by 143
Pereira, L., Igea, A., Cánovas, B., Dolado, I., & Nebreda, Á. R. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302732 · Cited by 142
Beck, D. J., & Brubaker, R. R. (1973) · Journal of Bacteriology · doi:10.1128/jb.116.3.1247-1252.1973 · Cited by 140
Dexeus, F. H., Logothetis, C. J., Sella, A., Amato, R. J., Kilbourn, R. G., Fitz, K., & Striegel, A. (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)38069-2 · Cited by 140
Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells
Gryparis, E. C., Hatziapostolou, M., Papadimitriou, Ε., & Avgoustakis, K. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.12.017 · Cited by 139
Arafa, E. A., Zhu, Q., Barakat, B. M., Wani, G., Zhao, Q., El‐Mahdy, M. A., & Wani, A. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1543 · Cited by 136
A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson, D. H., Forastiere, A. A., Arquette, M. A., Costa, F., Heelan, R. T., Huang, Y., & Kelsen, D. P. (2000) · PubMed · Cited by 135
Wick, M. J., Dong, L., Riojas, R. A., Ramos, F. J., & Liu, F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003937200 · Cited by 134
Zhang, C., Nance, E. A., Mastorakos, P., Chisholm, J., Berry, S., Eberhart, C. G., Tyler, B., Brem, H., Suk, J. S., & Hanes, J. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.007 · Cited by 134
Lee, R. H., Song, J. M., Park, M. Y., Kang, S. K., Kim, Y. K., & Jung, J. S. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00748-1 · Cited by 133
Yang, L., Li, N., Wang, H., Jia, X., Wang, X., & Luo, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1823 · Cited by 133
Cartei, G., Cartei, F., Cantone, A., Causarano, D., Genco, G., Tobaldin, A., Interlandi, G., & Giraldi, T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.10.794 · Cited by 133
DNA Repair capacity and cisplatin sensitivity of human testis tumour cells
Köberle, B., Grimaldi, K. A., Sunters, A., Hartley, J. A., Kèlland, L. R., & Masters, J. R. (1997) · International Journal of Cancer · Cited by 132
Evolution of Functions within the p53/p63/p73 Family
Laurenzi, V. D., & Melino, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05602.x · Cited by 130
Protection of renal cells from cisplatin toxicity by cell cycle inhibitors
Price, P. M., Safirstein, R. L., & Megyesi, J. K. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00192.2003 · Cited by 128
Katano, K., Safaei, R., Samimi, G., Holzer, A. K., Rochdi, M., & Howell, S. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.2.466 · Cited by 128
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Hashemi, F., Moghadam, E. R., Owrang, M., Hashemi, F., Makvandi, P., Goharrizi, M. A. S., Najafi, M., et al. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109871 · Cited by 127
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas, T., Stathopoulos, G. P., Volakakis, N., & Vougiouka, M. (2005) · PubMed · Cited by 126
Cisplatin-induced ototoxicity: Transporters playing a role in cisplatin toxicity
Sofia Waissbluth, A., & Daniel, S. J. (2013) · Hearing Research · doi:10.1016/j.heares.2013.02.002 · Cited by 121
Protective Role for c-Jun in the Cellular Response to DNA Damage
Potapova, O., Basu, S., Mercola, D., & Holbrook, N. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102075200 · Cited by 121
Metallothionein (MT)-Null Mice Are Sensitive to Cisplatin-Induced Hepatotoxicity
Liu, J., Liu, Y., Habeebu, S. S., & Klaassen, C. D. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8325 · Cited by 118
Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0205 · Cited by 117
Transport of Cisplatin by the Copper Efflux Transporter ATP7B
Safaei, R., Otani, S., Larson, B. J., Rasmussen, M. L., & Howell, S. B. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.040980 · Cited by 114
Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis
Liu, W., Wang, W., Wang, X., Xu, C., Zhang, N., & Di, W. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.024 · Cited by 113
Sakamoto, M., Kondo, A., Kawasaki, K., Goto, T., Sakamoto, H., Miyake, K., Koyamatsu, Y., Akiya, T., Iwabuchi, H., Muroya, T., et al. (2001) · PubMed · Cited by 110
Zhang, J., Miao, L., Guo, S., Zhang, Y., Zhang, L., Satterlee, A., Kim, W. Y., & Huang, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.016 · Cited by 110
Wang, X., Zhang, F., & Wu, X. (2017) · Scientific Reports · doi:10.1038/srep45983 · Cited by 109
Huang, Z., Zhang, Y., Li, H., Zhou, Y., Zhang, Q., Chen, R., Jin, T., Hu, K., Li, S., Wang, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2177-x · Cited by 108
Cardiotoxicity: Cisplatin and long-term cancer survivors
Patanè, S. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.238 · Cited by 102
Belyanskaya, L. L., Hopkins-Donaldson, S., Kurtz, S., Simões‐Wüst, A. P., Yousefi, S., Simon, H., Stahel, R. A., & Zangemeister‐Wittke, U. (2005) · International Journal of Cancer · doi:10.1002/ijc.21242 · Cited by 101
Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy
Domínguez-Ríos, R., Sánchez-Ramírez, D. R., Ruiz-Saray, K., Oceguera-Basurto, P. E., Almada, M., Juárez, J., Zepeda‐Moreno, A., Toro‐Arreola, A. D., Topete, A., & Daneri‐Navarro, A. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.03.011 · Cited by 101
Wang, Y., Qian, J., Yang, M., Xu, W., Wang, J., Hou, G., Ji, L., & Suo, A. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115206 · Cited by 101
Vitamin D in combination cancer treatment
Ma, Y., Trump, D. L., & Johnson, C. S. (2010) · Journal of Cancer · doi:10.7150/jca.1.101 · Cited by 98
A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1
Luca, A. D., Parker, L. J., Ang, W. H., Rodolfo, C., Gabbarini, V., Hancock, N. C., Palone, F., Mazzetti, A. P., Menin, L., Morton, C. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903297116 · Cited by 97
Cisplatin‐conjugated gold nanoparticles as a theranostic agent for head and neck cancer
Davidi, E. S., Dreifuss, T., Motiei, M., Shai, E., Bragilovski, D., Lubimov, L., Kindler, M. J. J., Popovtzer, A., Don, J., & Popovtzer, R. (2017) · Head & Neck · doi:10.1002/hed.24935 · Cited by 95
c-Abl stabilizes p73 by a phosphorylation-augmented interaction.
Tsai, K. K., & Yuan, Z.-M. (2003) · PubMed · Cited by 93
Low renal toxicity of lipoplatin compared to cisplatin in animals.
Devarajan, P., Tarabishi, R., Mishra, J., Ma, Q., Kourvetaris, A., Vougiouka, M., & Boulikas, T. (2004) · PubMed · Cited by 91
Park, S. H., Lee, Y., Han, S. H., Kwon, S. Y., Kwon, O. S., Kim, S. S., Kim, J. H., Park, Y. H., Lee, J. N., Bang, S., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-3 · Cited by 88
Therapeutic and biological activities of berberine: The involvement of Nrf2 signaling pathway
Ashrafizadeh, M., Fekri, H. S., Ahmadi, Z., Farkhondeh, T., & Samarghandian, S. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29392 · Cited by 87
Ashrafizadeh, M., Ahmadi, Z., Samarghandian, S., Mohammadinejad, R., Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117329 · Cited by 84
Cisplatin Induces p53-Dependent FLICE-Like Inhibitory Protein Ubiquitination in Ovarian Cancer Cells
Abedini, M. R., Muller, É., Brun, J., Bergeron, R., Gray, D. A., & Tsang, B. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0673 · Cited by 83
Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375
Tan, Y., Zhao, P., Rong, Z., Li, B., Xue, H., You, J., He, C., Li, W., He, X., Lee, R. J., et al. (2015) · Theranostics · doi:10.7150/thno.13130 · Cited by 83
Calculation of the Hydrophobicity of Platinum Drugs
Platts, J. A., Hibbs, D. E., Hambley, T. W., & Hall, M. D. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001080k · Cited by 82
Nephroprotective effect of bee honey and royal jelly against subchronic cisplatin toxicity in rats
Ibrahim, A., Eldaim, M. A. A., & Abdel‐Daim, M. M. (2015) · Cytotechnology · doi:10.1007/s10616-015-9860-2 · Cited by 81
Sirichanchuen, B., Pengsuparp, T., & Pithi Chanvorachote, B. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1199-1 · Cited by 81
Chen, H., Song, I., Hossain, A., Choi, M., YAMANE, Y., Zheng, L., Lu, J., Wu, L. Y. H., Siddik, Z. H., Klomp, L. W. J., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047969 · Cited by 80
Chen, P., Li, J., Jiang, H., Lan, T., & Chen, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2996-4 · Cited by 79
Khan, M. W., Zhao, P., Asifullah, K., Raza, F., Raza, S. M., Sarfraz, M., Chen, Y., Li, M., Tan, Y., Ma, X., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s196651 · Cited by 79
藤田, 昭., Fukuoka, S., Takabatake, H., Tagaki, S., & Sekine, K. (2000) · Oncology · doi:10.1159/000012185 · Cited by 75
Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer
Ranasinghe, R., & Eri, R. D. (2018) · Medicina · doi:10.3390/medicina54050088 · Cited by 75
Autophagy as a molecular target of quercetin underlying its protective effects in human diseases
Ashrafizadeh, M., Ahmadi, Z., Farkhondeh, T., & Samarghandian, S. (2019) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2019.1671458 · Cited by 74
Ghaferi, M., Amari, S., Mohrir, B. V., Raza, A., Shahmabadi, H. E., & Alavi, S. E. (2020) · Pharmaceuticals · doi:10.3390/ph13030044 · Cited by 74
Mirrahimi, M., Khateri, M., Beik, J., Ghoreishi, F. S., Dezfuli, A. S., Ghaznavi, H., & Shakeri‐Zadeh, A. (2019) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34356 · Cited by 72
Huang, Z., Zhang, Y., Li, H., Zhou, Y., Zhang, Q., Chen, R., Jin, T., Hu, K., Li, S., Wang, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2389-0 · Cited by 72
Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ
Basu, A., & Tu, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.199 · Cited by 70
Jiang, X., Zhu, X., Xu, H., Zhao, Z., Li, S., Li, S.-Z., Cai, J.-H., & Cao, J. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.176 · Cited by 70
Leekha, A., Gurjar, B. S., Tyagi, A., Rizvi, M. M. A., & Verma, A. K. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2235-z · Cited by 69
GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells.
Zhang, N., Gq, Y., Xm, S., & Wei, L. (2016) · PubMed · Cited by 67
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
Ahmed, E. M., Bandopadhyay, G., Coyle, B., & Grabowska, A. M. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0374-8 · Cited by 67
Decreased cisplatin uptake by resistant L1210 leukemia cells
Hromas, R., North, J. A., & Burns, C. P. (1987) · Cancer Letters · doi:10.1016/0304-3835(87)90091-7 · Cited by 65
Toro-Córdova, A., Flores-Cruz, M., Santoyo‐Salazar, J., Carrillo-Nava, E., Jurado, R., Figueroa-Rodriguez, P., López‐Sánchez, P., Medina, L. A., & García‐López, P. (2018) · Molecules · doi:10.3390/molecules23092272 · Cited by 65
Vivero-Escoto, J. L., & Elnagheeb, M. (2015) · Nanomaterials · doi:10.3390/nano5042302 · Cited by 64
Metadata
- Authors
- Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S.
- Venue
- Journal of Experimental Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2021-03
- Volume
- Volume 13
- Pages
- 303-328
- ISSN
- 1179-1454 (ISSN-L)
- OpenAlex
- W3137126526
- Cited by
- 384
- References
- 241
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.